Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020

Regulatory

STOCKHOLM, 19 August 2020 – Promore Pharma AB (publ) publishes its Interim report for the second quarter 2020 at 16.00 CET on 25 August 2020.

The next day, 26 February, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom, resigning CFO Jenni Björnulfson and the new CFO Erik Magnusson. After the presentation there will be a Q&A session. The presentation will be held in English. The conference can be accessed via computer, tablet or telephone.

The number of participants is limited and the company recommends that registration is done early to secure a seat. Registration for the web conference can be done by using the following link:

https://attendee.gotowebinar.com/register/8748674793280001550

The telephone conference and the presentation material will be available on the company´s website after the call; www.promorepharma.com.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
Email: jonas.ekblom@promorepharma.com

Jenni Björnulfson, CFO
Phone: [+46] 708 55 38 05
Email: jenni.bjornulfson@promorepharma.com

Promore Pharma’s Certified Adviser is Redeye AB.
Phone: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) is being evaluated in a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020

Documents